Cash, Cash Equivalents and Marketable Securities

As of September 30, 2013, Gilead had $2.76 billion of cash, cash equivalents and marketable securities compared to $2.58 billion as of December 31, 2012. During the first nine months of 2013, Gilead generated $2.38 billion in operating cash flow.

Full Year 2013 Guidance

Gilead revised its full year 2013 guidance, which it initially provided on February 4, 2013 and reiterated on July 25, 2013:
(In millions, except percentages and per share amounts)   Initially provided February 4, 2013;

Reiterated July 25, 2013
  Updated

October 29, 2013
Net Product Sales $10,000 - $10,200 $10,300 - $10,400
Non-GAAP*
Product Gross Margin 74% - 76% 74% - 76%
R&D $1,800 - $1,900 $1,950 - $2,000
SG&A $1,550 - $1,650 $1,500 - $1,550
Effective Tax Rate 26% - 28% 26% - 27%
 
Diluted EPS Impact of Acquisition-Related, Restructuring and Stock-Based Compensation Expenses $0.21 - $0.24 $0.21 - $0.24

* Non-GAAP product gross margin, expense and effective tax rate exclude the impact of acquisition-related, restructuring and stock-based compensation expenses, where applicable.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition